| Schedule of potential dilutive issuances |
| Schedule of potential
dilutive issuances | |
| |
| |
| |
|
| | |
Three Months Ended | |
Six Months Ended |
| | |
June 30, 2026 | |
June 30, 2025 | |
June 30, 2026 | |
June 30, 2025 |
| | |
| |
| |
| |
|
| Net income (loss) attributable to common stockholders | |
$ | (3,040,391 | ) | |
$ | (3,927,281 | ) | |
$ | (8,690,296 | ) | |
$ | (24,699,362 | ) |
| Derivative gain associated with warrants | |
| (1,151,120 | ) | |
| – | | |
| (9,094,691 | ) | |
| – | |
| Net income (loss) for dilutive calculation | |
$ | (4,191,511 | ) | |
$ | (3,927,281 | ) | |
$ | (17,784,987 | ) | |
$ | (24,699,362 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average shares outstanding | |
| 3,757,514,468 | | |
| 2,119,785,143 | | |
| 3,436,805,507 | | |
| 1,260,012,814 | |
| Dilutive effect of common stock warrants | |
| 216,800,000 | | |
| – | | |
| 216,800,000 | | |
| – | |
| Total diluted shares | |
| 3,974,314,468 | | |
| 2,119,785,143 | | |
| 3,653,605,507 | | |
| 1,260,012,814 | |
|
| Schedule of liabilities measured at fair value |
| Schedule of liabilities measured at fair value | |
| |
| |
|
| | |
Fair Value Measurements at June 30, 2026 |
| | |
Level 1 | |
Level 2 | |
Level 3 |
| Liabilities: | |
| | | |
| | | |
| | |
| Derivative liabilities | |
$ | – | | |
$ | – | | |
$ | 3,824,915 | |
| | |
Fair Value Measurements at December 31, 2025 |
| | |
Level 1 | |
Level 2 | |
Level 3 |
| Liabilities: | |
| |
| |
|
| Derivative liabilities | |
$ | – | | |
$ | – | | |
$ | 15,424,561 | |
|